Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
More info
13 Nov 2020
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN
Read more
06 Nov 2020
Menarini against cancer: for a child, ‘home’ means family
he Menarini Group continues to stand firmly by the side of the Tommasino Bacciotti Foundation
Read more
26 Oct 2020
Menarini Group: committed to fighting today's COVID-19 pandemic with an eye to averting similar health crises in the future
Elcin Barker Ergun, CEO of the Menarini Group, comments in a recent interview with ANSA what Menarini continues to do in the fight against the pandemic
Read more
26 Oct 2020
Press Release
Read more
25 Sep 2020
Radius Health & Menarini Group Provide Elacestrant Update
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.
Read more
17 Sep 2020
Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer
Menarini Ricerche today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611,
Read more
Page 1 of 6First   Previous   [1]  2  3  4  5  6  Next   Last